EPISODE · Feb 14, 2025 · 38 MIN
CAR-T in 2025: Advancements and the Road Ahead
Jason Westin, M.D., MS, FACP, MD Anderson Cancer Center, Houston, TX Recorded on January 21, 2025 Jason Westin, M.D., MS, FACP Professor, Department of Lymphoma & Myeloma Lead, Lymphoma & Myeloma Service Line Director, Lymphoma Clinical Research Section Chief, Aggressive and Indolent Lymphoma MD Anderson Cancer Center Houston, TX In this episode, Dr. Jason Westin from MD Anderson Cancer Center in Houston, Texas explores CAR T-cell therapy, covering both current and emerging indications. He highlights the educational needs of patients and caregivers, as well as the essential role of community and academic collaboration before and after treatment. Dr. Westin also discusses the use of minimal/measurable residual disease (MRD) in treatment planning, future directions of CAR-T, and ongoing clinical trials. Tune in to stay up-to-date on the latest advancements in CAR T-cell therapy! This episode is supported by Allogene Therapeutics, Bristol Myers Squibb, Johnson& Johnson & Legend Biotech, and Kite, a Gilead Company.
NOW PLAYING
CAR-T in 2025: Advancements and the Road Ahead
No transcript for this episode yet
Similar Episodes
May 4, 2026 ·16m
Apr 27, 2026 ·17m
Apr 13, 2026 ·16m
Apr 6, 2026 ·16m
Mar 30, 2026 ·16m
Mar 23, 2026 ·17m